Metronomic Chemotherapy in Elderly Patients

[21] Rikkert MO(2017)Resistance to metronomic chemotherapy and ways to overcome it Cancer Lett. 400 311-451

[22] Rockwood K(2023)Toxicity profile, adverse drug reactions and drug-drug interactions among geriatric cancer patients under metronomic chemotherapy in a South Indian tertiary care hospital J Oncol Pharm Pract 29 778-42410

[23] Kareva I(2022)Global increase in breast cancer incidence: risk factors and preventive measures Biomed Res Int. 2022 9605439-35

[24] Waxman DJ(2019)Breast cancer statistics, 2019 CA Cancer J Clin. 69 438-336

[25] Klement GL(2015)Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer Oncotarget. 6 42396-3400

[26] Tralongo AC(2015)On and off metronomic oral vinorelbine in elderly women with advanced breast cancer Tumori. 101 30-306

[27] Fratamico RS(2018)Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group Lancet Oncol. 19 323-e8

[28] Russo C(2021)Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2− breast cancer resistant to endocrine therapy: VinoMetro—AGO-B-046 J Cancer Res Clin Oncol. 147 3391-3628

[29] Sbrana A(2010)Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer Clin Breast Cancer. 10 301-137

[30] Antonuzzo A(2017)Efficacy and safety of vinorelbine-capecitabine oral metronomic combination in elderly metastatic breast cancer patients: VICTOR-1 study Tumori. 103 e4-696

[21] Rikkert MO(2017)Resistance to metronomic chemotherapy and ways to overcome it Cancer Lett. 400 311-451

[22] Rockwood K(2023)Toxicity profile, adverse drug reactions and drug-drug interactions among geriatric cancer patients under metronomic chemotherapy in a South Indian tertiary care hospital J Oncol Pharm Pract 29 778-42410

[23] Kareva I(2022)Global increase in breast cancer incidence: risk factors and preventive measures Biomed Res Int. 2022 9605439-35

[24] Waxman DJ(2019)Breast cancer statistics, 2019 CA Cancer J Clin. 69 438-336

[25] Klement GL(2015)Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer Oncotarget. 6 42396-3400

[26] Tralongo AC(2015)On and off metronomic oral vinorelbine in elderly women with advanced breast cancer Tumori. 101 30-306

[27] Fratamico RS(2018)Pertuzumab and trastuzumab with or without metronomic chemotherapy for older patients with HER2-positive metastatic breast cancer (EORTC 75111-10114): an open-label, randomised, phase 2 trial from the Elderly Task Force/Breast Cancer Group Lancet Oncol. 19 323-e8

[28] Russo C(2021)Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2− breast cancer resistant to endocrine therapy: VinoMetro—AGO-B-046 J Cancer Res Clin Oncol. 147 3391-3628

[29] Sbrana A(2010)Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer Clin Breast Cancer. 10 301-137

[30] Antonuzzo A(2017)Efficacy and safety of vinorelbine-capecitabine oral metronomic combination in elderly metastatic breast cancer patients: VICTOR-1 study Tumori. 103 e4-696